Sep. 22 at 3:41 PM
$SLS The tolerability gap in REGAL.
GPS is a non-myelosuppressive maintenance immunotherapy. Main side effects: injection-site reactions, mostly grade 1 to 2 and self-limited. No treatment-related deaths in Phase 2. Because it's so well tolerated, REGAL has extended dosing into years 2, 3 and beyond, with patients alive, in remission, and still on maintenance.
Contrast venetoclax + azacitidine (
$ABBV), a common best-available-therapy backbone: grade 3+ thrombocytopenia 46%, febrile neutropenia 43%, neutropenia 43%. 86% had serious adverse events; 72% needed dose interruptions.
Caveat: cross-trial figures, different populations, not a head-to-head, and REGAL's arms stay blinded. Extended dosing shows durable survivors and tolerability, not the hazard ratio.
But the quality-of-life case is real: a maintenance shot you can give for years vs. heavy myelosuppression.
